Hepatitis delta: recent advances and future therapies

References

• Shen D-T, Ji D-Z, Chen H-Y, et al. Hepatitis D: not a rare disease anymore: global update for 2017–2018. Gut. 2020;69:786–788. doi:10.1136/gutjnl-2019-318691
   PubMed Web of Science ®Google Scholar
• Heller T, Buti M, Lampertico P, et al. Hepatitis D: looking back, looking forward, seeing the reward and the promise. Clin. Gastroenterol. Hepatol. 2023;21:2051–2064. doi:10.1016/j.cgh.2023.04.022
   Web of Science ®Google Scholar
• Brunetto MR, Ricco G, Negro F, et al. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2):433–460. doi:10.1016/j.jhep.2023.05.001
   PubMed Web of Science ®Google Scholar
• Lok AS, Negro F, Asselah T, et al. Endpoints and new options for treatment of chronic hepatitis D. Hepatology. 2021;74:3479–3485. doi:10.1002/hep.32082
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Keskin O, Kalkan Ç, et al. Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease. J Infect Dis. 2018;217:1184–1192. doi:10.1093/infdis/jix656
   PubMed Web of Science ®Google Scholar
• Niro G, Smedile A, Fontana R, et al. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Therapeut. 2016;44:620–628. doi:10.1111/apt.13734
   PubMed Web of Science ®Google Scholar
• Sandmann L, Yurdaydin C, Deterding K, et al. HBcrAg levels are associated with virological response to treatment with interferon in patients with hepatitis delta. Hepatol Commun. 2022;6:480–495. doi:10.1002/hep4.1821
   PubMed Web of Science ®Google Scholar
• Metin O, Zeybel M, Yurdaydin C. Treatment endpoints for chronic hepatitis D. Liver Inter. 2023;43:60–68. doi:10.1111/liv.15447
   PubMed Web of Science ®Google Scholar
• Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Therapeut. 2014;40:93–104. doi:10.1111/apt.12788
   PubMed Web of Science ®Google Scholar
• Sandmann L, Wedemeyer H. Interferon-based treatment of chronic hepatitis D. Liver Inter. 2022;43:69–79. doi:10.1111/liv.15410
   PubMed Web of Science ®Google Scholar
• Volz T, Allweiss L, MBarek MB, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861–867. doi:10.1016/j.jhep.2012.12.008
   PubMed Web of Science ®Google Scholar
• Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnol. 2008;26:335–341. doi:10.1038/nbt1389
   PubMed Web of Science ®Google Scholar
• Lütgehetmann M, Mancke LV, Volz T, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685–694. doi:10.1002/hep.24758
   PubMed Web of Science ®Google Scholar
• Blank A, Meier K, Urban S, et al. Drug–drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro. Antiviral Ther. 2018;23:267–275. doi:10.3851/IMP3206
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. [Internet] Hepcludex: EPAR - Product information. 2023 [ cited 2024 Apr 26]. Available from: www.ema.europa.eu/en/documents/product-information/hepcludex-epar-product-information_en.pdf
   Google Scholar
• Zhu V, Burhenne J, Weiss J, et al. Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers. Front Pharmacol. 2023;14:1128547. doi:10.3389/fphar.2023.1128547
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Aleman S, Brunetto MR, et al. A Phase III, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22–32. doi:10.1056/NEJMoa2213429
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Schöneweis K, Bogomolov P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, Phase II trial. Lancet Infect Dis. 2023;23:117–129. doi:10.1016/S1473-3099(22)00318-8
   PubMed Web of Science ®Google Scholar
• Visco Comandini U, De Santis E, De Maria F, et al. “Real world” efficacy of bulevirtide in HBV/HDV-related cirrhosis including people living with HIV: results from the compassionate use programme at INMI Spallanzani in Rome, Italy. HIV Med. 2023;24:1075–1082. doi:10.1111/hiv.13518
   PubMed Web of Science ®Google Scholar
• de Lédinghen V, Fougerou-Leurent C, Le Pabic E, et al. Treatment With Bulevirtide in HIV Infected patients With chronic Hepatitis Delta. ANRS HD EP01 BULEDELTA & Compassionate Cohort. JHEP Reports. 2024;101057. doi:10.1016/j.jhepr.2024.101057
   PubMedGoogle Scholar
• Wedemeyer H, Aleman S, Brunetto MR, et al. Efficacy and Safety of Bulevirtide 2 mg or 10 mg for 96 Weeks in Chronic Hepatitis Delta, Including in 2 Patients With HIV/Hepatitis B Virus/Hepatitis Delta Virus. 31^st Annual Conference of Retroviruses and Opportunistic Infections. Denver, Colorado; 2024 Mar 3–6.
   Google Scholar
• Dietz-Fricke C, Tacke F, Zöllner C, et al. Treating hepatitis D with bulevirtide–Real-world experience from 114 patients. JHEP Reports. 2023;5:100686. doi:10.1016/j.jhepr.2023.100686
   PubMedGoogle Scholar
• Bazinet M, Pântea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, Phase II trial. Lancet Gastroenterol Hepatol. 2017;2:877–889. doi:10.1016/S2468-1253(17)30288-1
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Schoeneweis K, Bogomolov P, et al. Final results of a multicenter, open-label Phase II clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2019;70:e81. doi:10.1016/S0618-8278(19)30141-0
   Web of Science ®Google Scholar
• Asselah T, Arama SS, Bogomolov P, et al. Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa-2a in patients with chronic hepatitis delta: 24 weeks interim data of MYR204 Phase IIb study. J Hepatol. 2021;75:S291.
   Web of Science ®Google Scholar
• Asselah T, Lampertico P, Wedemeyer H, et al. 5009: efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: Primary endpoint results froma Phase IIb open-label, randomised, multicenter study MYR204. The Liver Meeting, American Association for the Study of Liver Diseases. Boston, MA; 2023 Nov 10–14.
   Google Scholar
• Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nature Immunol. 2015;16:802–809. doi:10.1038/ni.3212
   PubMed Web of Science ®Google Scholar
• Etzion O, Hamid SS, Lurie Y, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. J Hepatol. 2019;70:e32. doi:10.1016/S0618-8278(19)30058-1
   Web of Science ®Google Scholar
• Koh C, Hercun J, Rahman F, et al. A Phase II study of peginterferon lambda, lonafarnib and ritonavir for 24 weeks: end-of-treatment results from the lift HDV study. J Hepatol. 2020;73:S130. doi:10.1016/S0168-8278(20)30774-1
   PubMed Web of Science ®Google Scholar
• clinicalTrials.gov [Internet]. Phase III Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2). 2023 [ cited 2024 May 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05070364
   Google Scholar
• Eiger Biopharmaceuticals. [Internet] Eiger to Discontinue Phase III LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta [Internet]. 2023 [ cited 2024 May 5]. Available from: https://ir.eigerbio.com/news-releases/news-release-details/eiger-discontinue-phase-3-limt-2-trial-peginterferon-lambda
   Google Scholar
• Lange F, Garn J, Anagho HA, et al. Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell-derived hepatocytes. Liver Inter. 2023;43(10):2116–2129. doi:10.1111/liv.15655
   PubMed Web of Science ®Google Scholar
• Dhillon S. Lonafarnib: first approval. Drugs. 2021;81:283–289. doi:10.1007/s40265-020-01464-z
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Keskin O, Kalkan Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018;67:1224–1236. doi:10.1002/hep.29658
   PubMed Web of Science ®Google Scholar
• Etzion O, Hamid S, Asselah T, et al. GS-012 week 48 results of the Phase III D-LIVR Study: a randomized double- blind, placebo-controlled trial, evaluating the safety and efficacy of lonafarnib-boosted with ritonavir with or without peginterferon alfa in patients with chronic hepatitis delta. J Hepatol. 2023;78(Suppl. 1):S10. doi:10.1016/S0168-8278(23)00451-8
   Google Scholar
• Yurdaydin C, Keskin O, Yurdcu E, et al. A Phase II dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2022;75:1551–1565. doi:10.1002/hep.32259
   PubMed Web of Science ®Google Scholar
• Noordeen F, Scougall CA, Grosse A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLOS ONE. 2015;10:e0140909. doi:10.1371/journal.pone.0140909
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pântea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos (t) ide therapy. Gastroenterology. 2020;158:2180–2194. doi:10.1053/j.gastro.2020.02.058
   PubMed Web of Science ®Google Scholar
• Bourliere M, Loustaud-Ratti V, Stern C, et al. 1246-C: safety and efficacy of REP 2139-MG-based therapy in french patients with prior failure to PEGIFN and or Bulevirtide. Hepatology. 2023;78:S406–S407. doi:10.1016/S0168-8278(23)03284-1
   Google Scholar
• Replicor. [Internet] Pipeline. 2023 [ cited 2024 May 05]. Available from: http://replicor.com/pipeline/
   Google Scholar
• Wedemeyer H, Gane EJ, Agarwal K, et al. Treatment with siRNA JNJ-73763989 plus nucleos (t) ide analogue (NA) decreases HBsAg and HDV RNA levels in patients with chronic hepatitis D (CHD): part 1 of the REEF-D study. J Hepatol. 2023;78:S34. doi:10.1016/S0168-8278(23)00487-7
   Web of Science ®Google Scholar
• GSK plc. [Internet] GSK enters agreement to obtain exclusive license for JNJ- 3989 to expand the development of bepirovirsen. [ cited 2024 May 5]. Available from: www.gsk.com/media/10660/press-release-agreement-to-obtain-exclusive-license-for-jnj-3989-31-oct-2023.pdf
   Google Scholar
• Lempp FA, Volz T, Cameroni E, et al. Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice. J Hepatol. 2023;79(5):1129–1138. doi:10.1016/j.jhep.2023.07.003
   PubMed Web of Science ®Google Scholar
• Gane E, Jucov A, Dobryanska M, et al. Safety and Antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow up from the Phase II MARCH trial. J Hepatol. 2023;78:S34–S35. doi:10.1016/S0168-8278(23)00488-9
   Web of Science ®Google Scholar
• Asselah T, Streinu-Cercel A, Jucov A, et al. 5004: the monoclonal antibody VIR-3434 and siRNA VIR-2218 for the treatment of chronic hepatitis D virus: Preliminary results from the Phase II Solstice trial. The Liver Meeting, American Association for the Study of Liver Diseases. Boston, MA; 2023 Nov 10–14.
   Google Scholar
• Terrault NA, Lok AS, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Bolton N, Shang D, Agarwal K, et al. Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment. J Hepatol. 2022;77:S280. doi:10.1016/S0168-8278(22)00929-1
   Web of Science ®Google Scholar
• Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008–1015. doi:10.1016/j.jhep.2018.12.022
   PubMed Web of Science ®Google Scholar
• Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in, chronic hepatitis B and D-report from the 2022 AASLD-EASL HBV/HDV Treatment Endpoints Conference. J Hepatol. 2023;79:1254–1269. doi:10.1097/HEP.0000000000000431
   PubMedGoogle Scholar
• Usman Z, Velkov S, Protzer U, et al. HDVdb: a comprehensive hepatitis D virus database. Viruses. 2020;12:538. doi:10.3390/v12050538
   PubMed Web of Science ®Google Scholar
• Carey I, Anderson M, Lok J, et al. P130 Role of HDV genotype in HDV RNA positive patients–impact on disease progression and response to therapy with pegylated interferon. Gut. 2023;72:A100–A101. doi:10.1136/gutjnl-2023-BASL.144
   Web of Science ®Google Scholar
• Koh C, Surana P, Han T, et al. A Phase II study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis–end of study results from the LOWR HDV-3 study. J Hepatol. 2017;66:S101–S102. doi:10.1016/S0168-8278(17)30464-6
   Web of Science ®Google Scholar
• Wedemeyer H, Port K, Deterding K, et al. A Phase II dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study. J Hepatol. 2017;66:S24. doi:10.1016/S0168-8278(17)30310-0
   Web of Science ®Google Scholar
• Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled Phase IIA trial. Lancet Infect Dis. 2015;15:1167–1174. doi:10.1016/S1473-3099(15)00074-2
   PubMed Web of Science ®Google Scholar